Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.52 |
| ▸ | IL1RN | P18510 | 1/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | APC | P25054 | 3/20 | 0.47 |
| ▸ | NPY4R | P50391 | 5/20 | 0.45 |
| ▸ | NPY1R | P25929 | 4/20 | 0.45 |
| ▸ | NPY2R | P49146 | 4/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1370956 | 1.00 | NAALAD2 (0.52) | NAALAD2IL1RNERAP2OPRD1OPRM1 | |
| SCHEMBL1370963 | 0.94 | OPRD1 (0.47) | NAALAD2IL1RNERAP2OPRD1OPRM1 | |
| SCHEMBL1374043 | 0.94 | OPRD1 (0.47) | NAALAD2IL1RNERAP2OPRD1OPRM1 | |
| SCHEMBL15328626 | 0.92 | OPRD1 (0.55) | OPRD1OPRM1OPRK1 | |
| SCHEMBL29531333 | 0.92 | OPRD1 (0.55) | OPRD1OPRM1OPRK1 | |
| SCHEMBL15328632 | 0.92 | OPRD1 (0.55) | OPRD1OPRM1OPRK1 | |
| SCHEMBL30533128 | 0.91 | NAALAD2 (0.50) | NAALAD2 | |
| SCHEMBL31615028 | 0.90 | NAALAD2 (0.65) | NAALAD2IL1RNERAP2NPY4RNPY1R | |
| SCHEMBL31363027 | 0.89 | OPRD1 (0.56) | OPRD1OPRM1OPRK1NPY4R | |
| SCHEMBL31610861 | 0.89 | NAALAD2 (0.67) | NAALAD2IL1RNERAP2NPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC (CA) | 2016-09-15 | — | — | US | disclosed |
| EP-2794663-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2014-10-29 | — | — | EP | disclosed |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-11-24 | — | — | US | disclosed |
| WO-2010063124-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | NAALAD2 1123/4885IL1RN 1811/4885ERAP2 317/4885 |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | NAALAD2 1123/4885IL1RN 1811/4885ERAP2 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.